Page last updated: 2024-12-08
versicolorins
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
versicolorins: see also records for versicolorin A & versicolorin C; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 159258 |
MeSH ID | M0047738 |
Synonyms (7)
Synonym |
---|
9,10-anthracenedione, 1,6,8-trihydroxy-2-(hydroxymethyl)- |
versicolorins |
10088-98-9 |
1,6,8-trihydroxy-2-(hydroxymethyl)anthracene-9,10-dione |
DTXSID70143559 |
1402-25-1 |
1,6,8-trihydroxy-2-(hydroxymethyl)-9,10-dihydroanthracene-9,10-dione |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" Sensitivity to AFB1 increased with increasing age of the embryo, the model system showed a dose-response to increasing carcinogen concentrations, and one-half hour exposures appeared to be optimum for AFB1." | ( Rainbow trout (Salmo gairdneri) embryos: a sensitive animal model for experimental carcinogenesis. Hendricks, JD; Loveland, PM; Nixon, JE; Scanlan, RA; Sinnhuber, RO; Wales, JH, 1980) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 8 (57.14) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.57) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |